))
The impact of CAR-T therapy on the myeloma treatment landscape, patient selection for CAR-T & the evolving role of autoSCT
Manage episode 406592666 series 2838329
Content provided by VJHemOnc. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by VJHemOnc or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
The introduction of CAR-T therapy has revolutionized the myeloma treatment landscape, offering a promising therapeutic approach for patients with relapsed/refractory (R/R) disease. There are currently two approved CAR-T cells in multiple myeloma: idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), with ongoing studies exploring the possibility of bringing these agents into earlier lines of treatment.
In this podcast, Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, and Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discuss the significance of CAR-T therapy in myeloma, how to select patients for CAR-T therapy, the evolving role of autologous stem cell transplantation (autoSCT), and more.
200 episodes
Share
